Prelude Therapeutics Inc — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Huang Jane | President, CMO | Tax Withholding | 3,355 | $1.47 | $4,932 | 86,917 | Oct 4, 2025 |
| Huang Jane | President, CMO | Tax Withholding | 3,355 | $0.79 | $2,650 | 80,897 | Jul 4, 2025 |
| Huang Jane | President, CMO | Option Exercise | 9,375 | — | — | 78,232 | Apr 4, 2025 |
| Combs Andrew | Chief Chemistry Officer | Purchase | 100,000 | $0.69 | $69,000 | 480,123 | Mar 25, 2025 |
| Vaddi Krishna | CEO | Purchase | 675,000 | $0.69 | $465,750 | 1,999,296 | Mar 25, 2025 |
| Vaddi Krishna | CEO | Purchase | 15,000 | $0.73 | $10,950 | 1,324,296 | Mar 20, 2025 |
| Vaddi Krishna | CEO | Purchase | 29,999 | $0.75 | $22,499 | 1,294,774 | Mar 17, 2025 |
| Vaddi Krishna | CEO | Purchase | 50,000 | $0.72 | $36,000 | 1,264,775 | Mar 12, 2025 |
| Huang Jane | President, CMO | Tax Withholding | 3,859 | $1.39 | $5,364 | 68,857 | Jan 4, 2025 |
| Vaddi Krishna | CEO | Purchase | 5,000 | $1.21 | $6,050 | 142,553 | Dec 31, 2024 |
| Vaddi Krishna | CEO | Purchase | 10,000 | $1.20 | $12,000 | 137,553 | Dec 30, 2024 |
| Combs Andrew | Chief Chemistry Officer | Purchase | 60,000 | $1.37 | $82,200 | 377,623 | Dec 20, 2024 |
| Lim Bryant David | CLO, Interim CFO, Corp Sec. | Purchase | 25,000 | $0.91 | $22,750 | 27,400 | Dec 19, 2024 |
| Vaddi Krishna | CEO | Purchase | 6,888 | $0.89 | $6,130 | 127,553 | Dec 18, 2024 |
| Huang Jane | President, CMO | Option Exercise | 9,375 | — | — | 66,690 | Oct 4, 2024 |
| Huang Jane | President, CMO | Tax Withholding | 3,347 | $3.60 | $12,049 | 57,315 | Jul 4, 2024 |
| Huang Jane | President, CMO | Tax Withholding | 3,347 | $4.74 | $15,865 | 51,287 | Apr 4, 2024 |
| Huang Jane | President, CMO | Tax Withholding | 3,844 | $3.77 | $14,492 | 45,259 | Jan 4, 2024 |
| Huang Jane | President, CMO | Option Exercise | 9,375 | — | — | 39,728 | Oct 4, 2023 |
| Huang Jane | President, CMO | Tax Withholding | 3,242 | $4.65 | $15,075 | 30,353 | Jul 4, 2023 |
| Vaddi Krishna | CEO | Purchase | 900 | $5.31 | $4,779 | 1,067,275 | May 24, 2023 |
| Lim Bryant David | Chief Legal Officer, Corp Sec. | Purchase | 2,400 | $5.39 | $12,936 | 2,400 | May 24, 2023 |
| Chardonnet Laurent | Chief Financial Officer | Purchase | 5,000 | $5.50 | $27,500 | 42,165 | May 23, 2023 |
| Vaddi Krishna | CEO | Purchase | 11,856 | $5.63 | $66,749 | 1,065,375 | May 23, 2023 |
| ORBIMED CAPITAL LLC | — | Purchase | 869,565 | $5.75 | $4,999,999 | 10,119,756 | May 22, 2023 |
| Bonita David P | — | Purchase | 869,565 | $5.75 | $4,999,999 | 10,119,756 | May 22, 2023 |
| Huang Jane | President, CMO | Option Exercise | 37,500 | — | — | 37,500 | Apr 6, 2023 |
| Vaddi Krishna | CEO | Purchase | 19,188 | $5.13 | $98,434 | 120,665 | Dec 20, 2022 |
| Chardonnet Laurent | Chief Financial Officer | Purchase | 10,000 | $4.76 | $47,600 | 35,873 | Dec 8, 2022 |
| Chardonnet Laurent | Chief Financial Officer | Purchase | 10,000 | $4.23 | $42,300 | 24,500 | Jun 1, 2022 |
| Combs Andrew | EVP, Head of Chemistry | Option Exercise | 36,062 | $1.89 | $68,157 | 304,442 | Mar 31, 2022 |
| Chardonnet Laurent | Chief Financial Officer | Award / Grant | 6,500 | $7.51 | $48,815 | 14,500 | Mar 21, 2022 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Option Exercise | 3,016 | $1.89 | $5,700 | 3,460 | Dec 15, 2021 |
| Combs Andrew | EVP, Head of Chemistry | Purchase | 4,000 | $11.60 | $46,400 | 268,380 | Dec 13, 2021 |
| Chardonnet Laurent | Chief Financial Officer | Award / Grant | 5,000 | $12.28 | $61,400 | 8,000 | Dec 13, 2021 |
| Vaddi Krishna | President, CEO | Award / Grant | 8,000 | $12.13 | $97,040 | 1,053,519 | Dec 13, 2021 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Sale | 28,351 | $15.87 | $449,930 | 844 | Nov 16, 2021 |
| Mauro David J | Chief Medical Officer | Option Exercise | 15,000 | $1.89 | $28,350 | 15,000 | Oct 5, 2021 |
| Mauro David J | Chief Medical Officer | Sale | 4,640 | $37.79 | $175,346 | — | Sep 7, 2021 |
| Pierce Christopher | EVP and Chief of Business Oper | Sale | 6,930 | $42.50 | $294,525 | 3,750 | Sep 2, 2021 |
| Scherle Peggy | Chief Scientific Officer | Sale | 2,707 | $36.23 | $98,075 | 173,527 | Aug 26, 2021 |
| Piper Brian | Chief Financial Officer | Sale | 3,889 | $33.23 | $129,231 | 2,344 | Aug 25, 2021 |
| Scherle Peggy | Chief Scientific Officer | Sale | 2,286 | $35.07 | $80,170 | 172,920 | Aug 13, 2021 |
| Mauro David J | Chief Medical Officer | Sale | 2,063 | $31.03 | $64,015 | 6,821 | Aug 5, 2021 |
| Scherle Peggy | Chief Scientific Officer | Option Exercise | 20,000 | $1.43 | $28,600 | 192,920 | Jul 27, 2021 |
| Mauro David J | Chief Medical Officer | Sale | 10,445 | $27.17 | $283,791 | 4,555 | Jul 6, 2021 |
| Mauro David J | Chief Medical Officer | Sale | 12,700 | $32.73 | $415,671 | — | Jun 7, 2021 |
| Piper Brian | Chief Financial Officer | Sale | 1,736 | $35.45 | $61,541 | 399 | May 25, 2021 |
| Scherle Peggy | Chief Scientific Officer | Sale | 3,964 | $40.30 | $159,749 | 178,956 | May 7, 2021 |
| Mauro David J | Chief Medical Officer | Sale | 3,415 | $39.36 | $134,414 | 11,585 | May 5, 2021 |